---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116307"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:07:05.088289+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q3 product sales up 20% to $7.8M, gross margin improves to 72%, STAR-T data expected year-end

## Summary
- Q3 product sales $7.8M (+20% YoY); total revenue $8.8M (+9% YoY).
- Product gross margin 72% vs 55% a year ago, driven by manufacturing efficiencies.
- Pivotal STAR-T trial database lock nearing; initial data analysis expected before year-end.
- Cash and restricted cash $10.0M; company exploring alternative financing after terminating equity offering.
- Over 221,000 CytoSorb devices delivered cumulatively; expansion in Brazil approved for shock treatment.

## SEC filing metadata
- accession: 0001104659-23-116307
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/0001104659-23-116307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/tm2330311d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116307
- JSON: https://secwatch.observer/filing/0001104659-23-116307.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116307.txt

## Key facts
- Earnings Releases
  Cytosorbents Corp reported the quarter ended September 30, 2023 results: revenue Total revenue for Q3 2023, including product sales and grant income, was $8.8 million.
  - Period: the quarter ended September 30, 2023
  - Revenue: Total revenue for Q3 2023, including product sales and grant income, was $8.8 million
  - Result: reported results
  source text: On November 9, 2023, CytoSorbents Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/0001104659-23-116307-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.